Skip to content Skip to footer
Subscribe Now
Viewpoints_Anabela Cardoso_Mark Genovese
VIEWPOINTS

Lilly at ACG 2024: Anabela Cardoso and Mark Genovese in Conversation with PharmaShots

Shots: Lilly presented results from two long-term studies evaluating sustained efficacy in patients treated with mirikizumab for both moderately to severely active Ulcerative Colitis and Crohn’s Disease at ACG 2024 At three years, more than 80 percent of patients with moderately to severely active ulcerative colitis who were on remission sustained long-term remission and relief  …
March 24, 2025

Read more

Viewpoints_Mark Genovese 
VIEWPOINTS

Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study

Shots: Recently, at UEGW 2024, Lilly presented histologic and combined histologic-endoscopic outcomes from the VIVID-1 Phase III study, which evaluated the safety and efficacy of mirikizumab in adults with moderately to severely active Crohn’s disease A key finding reported during UEG Week highlighted the interactions between mirikizumab and ustekinumab, particularly regarding histologic response and remission,…
December 18, 2024

Read more

Viewpoints_Kevin Cammack
VIEWPOINTS

PharmaShots Interview: Eli Lilly’s Kevin Cammack Shares Insights on Lilly’s Collaboration with Global Diabetes Technology Companies

In an interview with PharmaShots, Kevin Cammack, Head of Connected Care, Eli Lilly and Company shares insights on the Lilly alliance with DexCom, Glooko, myDiabby Healthcare, and Roche to provide compatibility between their unique digital management platforms and Lilly's Tempo Pen and Tempo Smart Button.Shots:Eli Lilly collaborates with DexCom, Glooko, myDiabby Healthcare, and Roche to…
June 28, 2021

Read more